SK Life

SK Biopharmaceuticals is a global pharmaceutical company specializing in the research, development, and commercialization of treatments for central nervous system (CNS) disorders and oncology. The company's flagship product, XCOPRI (cenobamate), is an FDA-approved anti-seizure medication for adults with partial-onset seizures. Beyond epilepsy, the company is expanding its pipeline into radiopharmaceutical therapy (RPT) and targeted protein degradation (TPD) to address unmet needs in cancer. Headquartered in South Korea with a significant US presence via its subsidiary SK Life Science, the company leverages AI-driven drug discovery to accelerate its R&D efforts. SK Biopharmaceuticals is committed to becoming a global healthcare leader by providing innovative solutions for patients with complex neurological and oncological conditions.